Company profile: Lineage Cell Therapeutics
1.1 - Company Overview
Company description
- Provider of clinical-stage cellular therapies addressing unmet medical needs, including OpRegen for geographic atrophy secondary to age-related macular degeneration, OPC1 for spinal cord injury, ANP1 for auditory neuropathy spectrum disorders, PNC1 for photoreceptor dysfunction, RND1 hypoimmune pluripotent stem cell lines for CNS diseases, and a dendritic cell-based VAC immuno-oncology platform.
Products and services
- OPC1: An advanced-delivery cell therapy for spinal cord injury that focuses on improving motor function while enhancing safety through advanced delivery methods
- OpRegen: A clinical-stage cell therapy in trials for geographic atrophy secondary to age-related macular degeneration, engineered to improve retinal structure and function
- VAC Platform: A dendritic cell–based immuno-oncology platform that stimulates immune responses against cancer, with ongoing development spanning multiple cancer indications
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Lineage Cell Therapeutics
Synimmune
HQ: Germany
Website
- Description: Provider of innovative mono- and bispecific anti-tumor antibodies for treating life-threatening diseases, focusing on orphan hematopoietic malignancies; lead product candidate is the antibody FLYSYN.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Synimmune company profile →
Ultimovacs
HQ: Norway
Website
- Description: Provider of novel immunotherapies against cancer, including UV1, a peptide-based therapeutic cancer vaccine inducing a specific T cell response against the universal cancer antigen telomerase. Offers TET vaccine adjuvant technology targeting antigen-presenting cells, and conducts clinical trials (INITIUM, NIPU, DOVACC, FOCUS) evaluating UV1 with checkpoint inhibitors across melanoma, mesothelioma, ovarian, and head and neck cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ultimovacs company profile →
OncoResponse
HQ: United States
Website
- Description: Provider of immuno-oncology therapies leveraging human immune responses, with a proprietary human-antibody discovery platform sourcing antibodies from elite responder patients; OR2805 targeting M2-like tumor-associated macrophages; collaboration with MD Anderson; and a preclinical pipeline of monoclonal antibodies addressing immunosuppression in the tumor microenvironment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OncoResponse company profile →
Zymeworks
HQ: Canada
Website
- Description: Provider of computational biotechnology for optimizing therapeutic antibodies and other protein-based therapeutics, with a pipeline of bispecific antibodies and antibody-drug conjugates targeting HER2, folate receptor-α, mesothelin, glypican-3, and NaPi2b, including zanidatamab, zanidatamab zovodotin, ZW191, ZW171, ZW251, and ZW220.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Zymeworks company profile →
Amal Therapeutics
HQ: Switzerland
Website
- Description: Provider of proprietary oncology immunisation technology and therapeutic cancer vaccines, built on its KISIMA platform that delivers multiple antigens in a single vaccine. Offerings include ATP128, a clinical-stage therapeutic vaccine targeting metastatic colorectal cancer, and collaboration opportunities in immuno-oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amal Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Lineage Cell Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Lineage Cell Therapeutics
2.2 - Growth funds investing in similar companies to Lineage Cell Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Lineage Cell Therapeutics
4.2 - Public trading comparable groups for Lineage Cell Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →